Sirigen Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$64M
Sirigen General Information
Description
Developer of novel polymeric materials for the life-science and diagnostic industries. The company is the developer of light-harvesting polymeric materials, which offer high sensitivity flourescence (HSF) detection, with applications for drug testing, optimized detection techniques and developing next-generation diagnostic tools.
Contact Information
Website
www.sirigen.comCorporate Office
- Brightwater House
- Market Place
- Ringwood BH24 1AP
- England, United Kingdom
Corporate Office
- Brightwater House
- Market Place
- Ringwood BH24 1AP
- England, United Kingdom
Sirigen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 27-Aug-2012 | $64M | Completed | Generating Revenue | ||
| 8. Later Stage VC | 17-Feb-2012 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series G) | 13-Oct-2011 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series F) | 13-Nov-2010 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series E) | 09-Aug-2010 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series D) | 20-Apr-2010 | Completed | Generating Revenue | |||
| 3. Later Stage VC (Series C) | 01-Jun-2009 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 30-Apr-2008 | $5.4M | $5.4M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Mar-2006 | Completed | Product Development |
Sirigen Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C |
Sirigen Patents
Sirigen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2015163718-A | Novel reagents for directed biomarker signal amplification | Pending | 19-Jan-2010 |
Sirigen Signals
Sirigen Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARC InterCapital | Venture Capital | Minority | ||
| IQ Capital Partners | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Nesta | Limited Partner | Minority | ||
| Oxford Capital Partners | Venture Capital | Minority |
Sirigen Investments (1)
Sirigen’s most recent deal was a Seed Round with Let's Cram for . The deal was made on 19-Jan-2009.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Let's Cram | 19-Jan-2009 | Seed Round | Educational and Training Services (B2C) |
Sirigen FAQs
-
When was Sirigen founded?
Sirigen was founded in 2003.
-
Where is Sirigen headquartered?
Sirigen is headquartered in Ringwood, United Kingdom.
-
What is the size of Sirigen?
Sirigen has 15 total employees.
-
What industry is Sirigen in?
Sirigen’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Sirigen a private or public company?
Sirigen is a Private company.
-
What is the current valuation of Sirigen?
The current valuation of Sirigen is .
-
What is Sirigen’s current revenue?
The current revenue for Sirigen is .
-
How much funding has Sirigen raised over time?
Sirigen has raised $19M.
-
Who are Sirigen’s investors?
ARC InterCapital, IQ Capital Partners, , Nesta, and Oxford Capital Partners are 5 of 9 investors who have invested in Sirigen.
-
When was Sirigen acquired?
Sirigen was acquired on 27-Aug-2012.
-
Who acquired Sirigen?
Sirigen was acquired by Becton, Dickinson and Company.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process